Secondary hemophagocytic lymphohistiocytosis due to nivolumab/ipilimumab in a renal cell cancer patient—A case report

Secondary hemophagocytic lymphohistiocytosis due to nivolumab/ipilimumab in a renal cell cancer patient—A case report

Abstract Secondary immune‐related hemophagocytic lymphohistiocytosis is a rare but life‐threatening complication of immune checkpoint inhibitors. HLH‐2004 and HLH‐1994 guidelines originally developed for primary HLH are the only available guidelines. It has proven to have a good prognosis if diagnos...

Full description

Bibliographic Details
Main Authors: Adeel Masood, Ahsan Wahab, Tanya Clifford, Eric J. Weaver, Hamid Ehsan, Walid El Ayass
Format: Article
Language:English
Published: Wiley 2021-12-01
Series:Clinical Case Reports
Subjects:
hematology/oncology
HLH
immune checkpoint inhibitors
ipilimumab
nivolumab
pembrolizumab
Online Access:https://doi.org/10.1002/ccr3.5184

Internet

https://doi.org/10.1002/ccr3.5184

Similar Items